Jing Xu

1PUBLICATIONS
7CO-AUTHORS
Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

Sort by Publication Date:
|Jan 29, 2026
Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecan.

Jing Xu, Jing Liu, Yang Liu

Pageof 1

Frequent Collaborators

1 joint publications

Yong Yi

1 joint publications

Chuan Xu

1 joint publications

Qintong Li

1 joint publications

Yang Cao

1 joint publications

Peng Mi

1 joint publications

Zhi-Xiong Jim Xiao

1 joint publications

Mengmeng Niu

Frequent Collaborators

1 joint publications

Yong Yi

1 joint publications

Chuan Xu

1 joint publications

Qintong Li

1 joint publications

Yang Cao

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us

Top Related Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on : Dec 05, 2017

13.1K
See more related videos

Top Related Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on : Dec 05, 2017

13.1K
See more related videos